Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.
UK-based Lindus Health and US-based Thirty Madison today (December 14) announced they have completed the enrolment of a trial to assess their personalized dermatology telemedicine platform, Facet.
A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.
The Digital Medicine Society is offering a library of resources to help promote the use of nocturnal scratch as an endpoint for the troubling skin condition.
The pharmaceutical company's clinical study is intended to examine critical gaps in care for people of color living with moderate to severe plaque psoriasis.
The group is collaborating with AbbVie, Janssen, Novartis, Pfizer, and UCB to help advance nocturnal scratch as a digital endpoint for atopic dermatitis.
A leader from Swift Medical describes the company’s skin and wound management technology, and how their tech empowers patient capture of vital information.
Swift Skin and Wound is a digital imaging technology designed to support decentralized clinical trials conducted to evaluate skin and wound treatments.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Novartis Pharma AG partners with Target PharmaSolutions to support its global longitudinal observational study designed to generate real-world clinical data.
Evotec and Almirall are using a novel approach to disrupt cell signaling to discover and develop first-in-class therapeutics targeting dermatology diseases.
In Novartis’ latest restructuring move for 2018, the pharma giant announced plans to sell US generic oral solids and dermatology businesses to Aurobindo Pharma US.
LEO Pharma acquires Bayer’s prescription dermatology unit in a definitive agreement, in hopes of reaching their goal of being the leading global dermatology company by 2025.
Synteract has acquired the dermatology CRO Cu-Tech, opening a fifth center of development as part of its strategy to develop “highly-expert therapeutic areas of focus,” says CCO.